This article focuses on how to treat intellectual property (“IP”) and rights to IP in U.S. M&A transactions, particularly in the technology and life sciences sectors, in which IP often accounts for a substantial amount of Target’s value in the deal.
Author: Owen D. Kurtin
This article was originally published on the website of Kurtin PLLC in November 2022.
Members-only access
To access the full resource, you must be a member. Already a member? Login to unlock.
Login
Not an ACC member?
Gain access to a comprehensive collection of global resources for in-house counsel
Sign up for a 30-day trial
Region:
United States
The information in any resource collected in this virtual library should not be construed as legal advice or legal opinion on specific facts and should not be considered representative of the views of its authors, its sponsors, and/or ACC. These resources are not intended as a definitive statement on the subject addressed. Rather, they are intended to serve as a tool providing practical advice and references for the busy in-house practitioner and other readers.